Related Experiment Video
Updated: May 11, 2026
Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation
Published on: August 11, 2023
Anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide-stimulated BV2 microglial cells
Yu Young Lee1, Jin-Sun Park, Ji-Sun Jung
1Department of Molecular Medicine and Tissue Injury Defense Research Center, Ewha Womans University Medical School, Seoul 110-783, Korea. hskimp@ewha.ac.kr.
Abstract:
Microglia are resident immune cells in the central nervous system. They play a role in normal brain development and neuronal recovery. However, overactivation of microglia causes neuronal death, which is associated with neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Therefore, controlling microglial activation has been suggested as an important target for treatment of neurodegenerative diseases. In the present study, we investigated the anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide (LPS)-stimulated BV2 microglial cells and rat primary microglia. The data showed that Rg5 suppressed LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. In addition, Rg5 inhibited the mRNA expressions of iNOS, TNF-α, IL-1b, COX-2 and MMP-9 induced by LPS. Further mechanistic studies revealed that Rg5 inhibited the phophorylations of PI3K/Akt and MAPKs and the DNA binding activities of NF-kB and AP-1, which are upstream molecules controlling inflammatory reactions. Moreover, Rg5 suppressed ROS production with upregulation of hemeoxygenase-1 (HO-1) expression in LPS-stimulated BV2 cells. Overall, microglial inactivation by ginsenoside Rg5 may provide a therapeutic potential for various neuroinflammatory disorders.
Insights
Ginsenoside Rg5 reduces harmful microglial activation by suppressing inflammatory responses and oxidative stress. This suggests Rg5 as a potential treatment for neuroinflammatory disorders like Alzheimer's and Parkinson's diseases.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglia, the central nervous system's immune cells, are crucial for brain health but their overactivation contributes to neurodegenerative diseases.
- Controlling microglial activation is a key therapeutic strategy for neurodegenerative conditions.
Purpose of the Study:
- To investigate the anti-inflammatory effects of ginsenoside Rg5 on activated microglia.
- To explore the underlying mechanisms of Rg5's action in neuroinflammation.
Main Methods:
- Utilized lipopolysaccharide (LPS)-stimulated BV2 microglial cells and primary rat microglia.
- Assessed nitric oxide (NO) and pro-inflammatory cytokine (TNF-α) production.
- Measured mRNA expression of inflammatory markers (iNOS, TNF-α, IL-1b, COX-2, MMP-9).
- Investigated signaling pathways (PI3K/Akt, MAPKs) and transcription factors (NF-kB, AP-1).
- Evaluated reactive oxygen species (ROS) production and hemeoxygenase-1 (HO-1) expression.
Main Results:
- Ginsenoside Rg5 significantly suppressed LPS-induced NO production and TNF-α secretion.
- Rg5 inhibited the mRNA expression of iNOS, TNF-α, IL-1b, COX-2, and MMP-9.
- Rg5 reduced phosphorylation of PI3K/Akt and MAPKs, and inhibited NF-kB and AP-1 DNA binding.
- Rg5 suppressed ROS production and upregulated HO-1 expression in LPS-stimulated microglia.
Conclusions:
- Ginsenoside Rg5 demonstrates significant anti-inflammatory and antioxidant effects in microglia.
- Rg5 modulates key signaling pathways and transcription factors involved in neuroinflammation.
- Ginsenoside Rg5 shows therapeutic potential for neuroinflammatory disorders.